Innovation

I’ve been working on RWE most of my career and the clinical trial data for a while now. And 20 years ago, we would have never thought about merging them together but there’s a lot of opportunities if we do this.

The recent advances in analytical methods for combining evidence from RCTs and non-RCTs, and the development of new frameworks for the inclusion of RWE in HTA have provided a greater insight on how issues around RWE uncertainty can be dealt with when estimating treatment effects for new technologies.

Join our discussion today as Thomas and I talk about this.

During my early years, I was overwhelmed by so many trainings, SOPs, and processes. Only after my later years, I learned what quality is really about. Gary fundamentally helped me and many others have a very different and more insightful/helpful/easy perspective on this topic.

Data visualisation is one of my favorite topics and today, I’ll be interviewing someone who has helped me understand about data visualization for years.